Degradation mechanism and decomposition of sulfamethoxazole aqueous solution with persulfate activated by dielectric barrier discharge.

The present study focused on the degradation of sulfamethoxazole (SMX) aqueous solution and the toxicity of processing aqueous by the dielectric barrier discharge (DBD) activated persulfate (PS). The effects of input voltage, input frequency, duty cycle, and PS dosage ratio on the SMX degradation efficiency were measured. Based on the results of the Response Surface Methodology (RSM), SMX degradation efficiency reached 83.21% which is 10.54% higher than that without PS, and the kinetic constant was 0.067 min-1 in 30 min when the input voltage at 204 V (input power at 110.6 W), the input frequency at 186 Hz, the duty cycle at 63%, and the PS dosage ratio at 5.1:1. The addition of PS can produce more active particles reached 1.756 mg/L (O3), 0.118 mg/L (H2O2), 0.154 mmol/L (·OH) in 30 min. Furthermore, the DBD plasma system effectively activated an optimal amount of PS, leading to improved removal efficiency of COD, and TOC to 30.21% and 47.21%, respectively. Subsequently, eight primary by-products were pinpointed, alongside the observation of three distinct pathways of transformation. Predictions from the ECOSAR software indicated that most of the degradation intermediates were less toxic than SMX. The biological toxicity experiments elucidated that the treatment with the DBD/PS system effectively reduced the mortality of zebrafish larvae caused by SMX from 100% to 20.13% and improved the hatching rate from 55.69% to 80.86%. In particular, it is important to note that the degradation intermediates exhibit teratogenic effects on zebrafish larvae.

U-Shaped Association Between Monocyte-Lymphocyte Ratio and Risk of Cardiac Conduction Block.

Purpose: Inflammation plays a critical role in the development of cardiac conduction block (CCB), which is associated with an increased risk of morbidity and mortality. The monocyte-lymphocyte ratio (MLR) acts as a novel inflammatory marker; however, its association with CCB has not yet been studied. This study aimed to investigate the association between MLR and CCB risk. Patients and Methods: In total, 82,472 CCB-free participants were identified from the Kailuan study. MLR was calculated using the monocyte count/lymphocyte count. The participants were stratified based on quartiles of MLR levels. Incident CCB and its subtypes were ascertained from electrocardiograms at biennial follow-up visits. The Cox proportional hazards model and restricted cubic spline analysis were used to investigate the association between MLR with CCB and its subtypes. Results: During a median follow-up of 10.4 years, 3222 incident CCB cases were observed. A U-shaped association was observed between MLR and CCB risk (Pnonlinearity <0.05). After multivariate adjustment, individuals in the highest MLR quartile had a hazard ratio (HR) of 1.212 (95% CI: 1.097-1.340; Q4 vs Q2), while those in the lowest MLR quartile had an HR of 1.106 (95% CI: 1.000-1.224; Q1 vs Q2). Sensitivity and subgroup analyses yielded consistent results. The U-shaped association persisted for atrioventricular block (AVB) in subtype analyses. Conclusion: MLR was significantly associated with an increased risk of new-onset CCB. Assessing MLR may have clinical relevance for predicting CCB risk, providing valuable insights for preventive strategies and patient management. Pre-Registered Clinical Trial Number: The pre-registered clinical trial number is ChiCTR-TNC-11001489.